SCHEMBL20489573

SCHEMBL20489573

CSc1nc2ncc(C(=O)O)c(C3CC3)c2s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
HCRTR1 O43613 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM6B O15054 1/20 0.34
KDM4A O75164 1/20 0.34
KDM4D Q6B0I6 1/20 0.34
HIF1AN Q9NWT6 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
MGLL Q99685 1/20 0.34
NOTUM Q6P988 2/20 0.33
GPR35 Q9HC97 1/20 0.33
AADAT Q8N5Z0 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489433 0.89 SYK (0.35) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL20489536 0.83 KDM4E (0.34) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL20489542 0.83 LMNA (0.43) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL20489509 0.78 AADAT (0.36) AADATKDR
SCHEMBL20489406 0.76 GABRP (0.36) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL20489497 0.75 AADAT (0.41) KDM4ENOTUMAADATKDR
SCHEMBL20489633 0.73 AADAT (0.32) AADATKDR
SCHEMBL20489393 0.72 PDK2 (0.32) NOTUMKDR
SCHEMBL20489692 0.72 FABP4 (0.36) FABP4FABP5
SCHEMBL20489423 0.70 AADAT (0.33) KDM4EAADAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3372601-B1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2022-09-21 EP disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
EP-3372601-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2018-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND KAT2A, KAT7, KAT5 KDM4E 418/4885ALDH1A1 2879/4885HPGD 2234/4885
US-10793582-B2 Bicyclic heterocyclic compound KAT2A, KAT7, KAT5 KDM4E 383/4885ALDH1A1 2375/4885HPGD 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.